GSA Capital Partners’s aTyr Pharma ATYR Stock Holding History

GSA Capital Partners’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.31M	Sell	1,684,586 -946,052	-36%	-$799K	0.08%	348
2025 Q4	$2.06M	Buy	2,630,638 +1,923,907	+272%	+$1.58M	0.18%	77
2025 Q3	$510K	Buy	706,731 +210,442	+42%	+$954K	0.04%	839
2025 Q2	$2.52M	Buy	496,289 +163,965	+49%	+$645K	0.18%	72
2025 Q1	$1M	Buy	332,324 +57,898	+21%	+$211K	0.09%	340
2024 Q4	$993K	Sell	274,426 -12,174	-4%	-$36.9K	0.07%	417
2024 Q3	$504K	Sell	286,600 -35,860	-11%	-$65.2K	0.04%	902
2024 Q2	$503K	Buy	322,460 +98,313	+44%	+$171K	0.04%	962
2024 Q1	$437K	Buy	224,147 +114,983	+105%	+$201K	0.03%	970
2023 Q4	$154K	Buy	109,164 +81,605	+296%	+$105K	0.01%	1366
2023 Q3	$44K	Buy	+27,559	New	+$51K	﹤0.01%	1423
2022 Q1	–	Sell	-58,791	Closed	-$439K	–	1914
2021 Q4	$439K	Buy	+58,791	New	+$491K	0.06%	686
2016 Q3	–	Sell	-2,607	Closed	-$101K	–	2008
2016 Q2	$101K	Buy	+2,607	New	+$121K	0.01%	1667

Other funds holding ATYR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

GSA Capital Partners's ATYR Position: Q1 2026 in Review

GSA Capital Partners reduced its aTyr Pharma (ATYR) stake by 36% in Q1 2026, selling an estimated $799K and leaving 1,684,586 shares worth $1.31M. The position accounts for 0.08% of the portfolio, ranked #348.

GSA Capital Partners first reported a position in ATYR in Q2 2016 and has held it in 13 quarters since. The position peaked at $2.52M in Q2 2025. 111 funds tracked by Wall St. Rank hold ATYR as of Q1 2026.

GSA Capital Partners held 1,684,586 shares of aTyr Pharma worth $1.31M as of Q1 2026.
GSA Capital Partners sold 946,052 aTyr Pharma shares in Q1 2026, an estimated $799K.
aTyr Pharma made up 0.08% of GSA Capital Partners's portfolio in Q1 2026, its #348 holding.
GSA Capital Partners first reported a position in aTyr Pharma in Q2 2016 and has held it in 13 quarters since.
GSA Capital Partners's aTyr Pharma position peaked at $2.52M in Q2 2025.
111 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.